These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23609214)

  • 1. The synthetic cannabinoid withdrawal syndrome.
    Nacca N; Vatti D; Sullivan R; Sud P; Su M; Marraffa J
    J Addict Med; 2013; 7(4):296-8. PubMed ID: 23609214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic cannabinoid withdrawal: a new demand on detoxification services.
    Macfarlane V; Christie G
    Drug Alcohol Rev; 2015 Mar; 34(2):147-53. PubMed ID: 25588420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome.
    Sañudo-Peña MC; Force M; Tsou K; McLemore G; Roberts L; Walker JM
    Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1121-4. PubMed ID: 11216447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.
    Hopkins CY; Gilchrist BL
    J Emerg Med; 2013 Oct; 45(4):544-6. PubMed ID: 23890687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence].
    Vorspan F; Guillem E; Bloch V; Bellais L; Sicot R; Noble F; Lepine JP; Gorelick DA
    Encephale; 2011 Sep; 37(4):266-72. PubMed ID: 21981886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic cannabinoid intoxication: a case series and review.
    Harris CR; Brown A
    J Emerg Med; 2013 Feb; 44(2):360-6. PubMed ID: 22989695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic cannabinoid JWH-018 and psychosis: an explorative study.
    Every-Palmer S
    Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ["Spice"--synthetic cannabinoids with dangerous effects].
    Personne M; Westerbergh J; Hammer-Pettersen L
    Lakartidningen; 2014 Nov; 111(47):2105-7. PubMed ID: 25386644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study.
    Prilutskaya M; Bersani FS; Corazza O; Molchanov S
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological properties and dependence liabilities of synthetic cannabinoids].
    Funada M
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Jun; 45(3):167-74. PubMed ID: 20681249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gamma-hydroxybutyrate withdrawal syndrome.
    Dyer JE; Roth B; Hyma BA
    Ann Emerg Med; 2001 Feb; 37(2):147-53. PubMed ID: 11174231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of synthetic cannabinoids on electroencephalogram power spectra in rats.
    Uchiyama N; Kikura-Hanajiri R; Matsumoto N; Huang ZL; Goda Y; Urade Y
    Forensic Sci Int; 2012 Feb; 215(1-3):179-83. PubMed ID: 21640532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic cannabinoid presentations decline following ban.
    Christie G; MacFarlane V
    Drug Alcohol Rev; 2016 Mar; 35(2):E3-4. PubMed ID: 26492870
    [No Abstract]   [Full Text] [Related]  

  • 14. [Synthetic cannabinoids--the new "legal high" drugs].
    Berkovitz R; Arieli M; Marom E
    Harefuah; 2011 Dec; 150(12):884-7, 937. PubMed ID: 22352277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
    Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
    Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous cannabinoid withdrawal produces a differential time-related responsiveness in cannabinoid CB1 receptor gene expression in the mouse brain.
    Oliva JM; Ortiz S; Palomo T; Manzanares J
    J Psychopharmacol; 2004 Mar; 18(1):59-65. PubMed ID: 15107186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.
    Budney AJ; Vandrey RG; Hughes JR; Moore BA; Bahrenburg B
    Drug Alcohol Depend; 2007 Jan; 86(1):22-9. PubMed ID: 16769180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic cannabinoid use disorder: an update for general psychiatrists.
    Grigg J; Manning V; Arunogiri S; Lubman DI
    Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tripping with Synthetic Cannabinoids ("Spice"): Anecdotal and Experimental Observations in Animals and Man.
    Järbe TUC; Raghav JG
    Curr Top Behav Neurosci; 2017; 32():263-281. PubMed ID: 27753006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
    Cooper ZD
    Curr Psychiatry Rep; 2016 May; 18(5):52. PubMed ID: 27074934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.